Applicability of [11C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model

Applicability of [11C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment... In this study, we evaluated the anti-amyloid effect of functionalized nanoliposomes (mApoE-PA-LIP) in a mouse model of Alzheimer's disease with use of positron emission tomography and β-amyloid (Aβ)–targeted tracer [11C]Pittsburgh compound B ([11C]PIB). APP23 mice were injected with mApoE-PA-LIP or saline (3 times per week for 3 weeks) and [11C]PIB imaging was performed at baseline, after the treatment and after 3 months follow-up period, accompanied by Aβ immunohistochemistry and ELISA. After the treatment, [11C]PIB binding ratios between mApoE-PA-LIP and saline groups were equivalent in all analyzed brain regions; however, in the saline group, binding ratios increased from the baseline, whereas no increase was detected in the mApoE-PA-LIP group. During the additional follow-up, [11C]PIB binding increased significantly from baseline in both groups, and binding ratios correlated with the immunohistochemically defined Aβ load. This study further supports the use of [11C]PIB positron emission tomography imaging as a biomarker of Aβ deposition in APP23 mice and highlights the benefits of noninvasive follow-up, that is, using baseline data for animal stratification and normalization of treatment effects to baseline values, for future anti-amyloid treatment studies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurobiology of Aging Elsevier

Applicability of [11C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model

11 pages
Read Article

Loading next page...
 
/lp/elsevier/applicability-of-11c-pib-micro-pet-imaging-for-in-vivo-follow-up-of-Xs8e6rVNeQ
Publisher
Elsevier
Copyright
Copyright © 2017 The Authors
ISSN
0197-4580
DOI
10.1016/j.neurobiolaging.2017.05.008
Publisher site
See Article on Publisher Site

Abstract

In this study, we evaluated the anti-amyloid effect of functionalized nanoliposomes (mApoE-PA-LIP) in a mouse model of Alzheimer's disease with use of positron emission tomography and β-amyloid (Aβ)–targeted tracer [11C]Pittsburgh compound B ([11C]PIB). APP23 mice were injected with mApoE-PA-LIP or saline (3 times per week for 3 weeks) and [11C]PIB imaging was performed at baseline, after the treatment and after 3 months follow-up period, accompanied by Aβ immunohistochemistry and ELISA. After the treatment, [11C]PIB binding ratios between mApoE-PA-LIP and saline groups were equivalent in all analyzed brain regions; however, in the saline group, binding ratios increased from the baseline, whereas no increase was detected in the mApoE-PA-LIP group. During the additional follow-up, [11C]PIB binding increased significantly from baseline in both groups, and binding ratios correlated with the immunohistochemically defined Aβ load. This study further supports the use of [11C]PIB positron emission tomography imaging as a biomarker of Aβ deposition in APP23 mice and highlights the benefits of noninvasive follow-up, that is, using baseline data for animal stratification and normalization of treatment effects to baseline values, for future anti-amyloid treatment studies.

Journal

Neurobiology of Aging – Elsevier

Published: Sep 1, 2017

References

  • Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models
    Balducci, C.; Mancini, S.; Minniti, S.; La Vitola, P.; Zotti, M.; Sancini, G.; Mauri, M.; Cagnotto, A.; Colombo, L.; Fiordaliso, F.; Grigoli, E.; Salmona, M.; Snellman, A.; Haaparanta-Solin, M.; Forloni, G.; Masserini, M.; Re, F.
  • Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease
    Bana, L.; Minniti, S.; Salvati, E.; Sesana, S.; Zambelli, V.; Cagnotto, A.; Orlando, A.; Cazzaniga, E.; Zwart, R.; Scheper, W.; Masserini, M.; Re, F.
  • Liposomes as nanomedical devices
    Bozzuto, G.; Molinari, A.
  • Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET
    Brendel, M.; Delker, A.; Rötzer, C.; Böning, G.; Carlsen, J.; Cyran, C.; Mille, E.; Gildehaus, F.J.; Cumming, P.; Baumann, K.; Steiner, H.; Haass, C.; Herms, J.; Bartenstein, P.; Rominger, A.
  • Cross-sectional comparison of small animal [18F]-Florbetaben amyloid-PET between transgenic ad mouse models
    Brendel, M.; Jaworska, A.; Grießinger, E.; Rötzer, C.; Burgold, S.; Gildehaus, F.J.; Carlsen, J.; Cumming, P.; Baumann, K.; Haass, C.; Steiner, H.; Bartenstein, P.; Herms, J.; Rominger, A.
  • Monitoring of chronic γ-secretase modulator treatment by serial amyloid-PET
    Brendel, M.; Jaworska, A.; Herms, J.; Trambauer, J.; Rötzer, C.; Gildehaus, F.J.; Carlsen, J.; Cumming, P.; Bylund, J.; Luebbers, T.; Bartenstein, P.; Steiner, H.; Haass, C.; Baumann, K.; Rominger, A.
  • Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
    Dubois, B.; Feldman, H.H.; Jacova, C.; Hampel, H.; Molinuevo, J.L.; Blennow, K.; DeKosky, S.T.; Gauthier, S.; Selkoe, D.; Bateman, R.; Cappa, S.; Crutch, S.; Engelborghs, S.; Frisoni, G.B.; Fox, N.C.; Galasko, D.; Habert, M.O.; Jicha, G.A.; Nordberg, A.; Pasquier, F.; Rabinovici, G.; Robert, P.; Rowe, C.; Salloway, S.; Sarazin, M.; Epelbaum, S.; de Souza, L.C.; Vellas, B.; Visser, P.J.; Schneider, L.; Stern, Y.; Scheltens, P.; Cummings, J.L.
  • Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide
    Gobbi, M.; Re, F.; Canovi, M.; Beeg, M.; Gregori, M.; Sesana, S.; Sonnino, S.; Brogioli, D.; Musicanti, C.; Gasco, P.; Salmona, M.; Masserini, M.E.
  • Biological markers of amyloid beta-related mechanisms in Alzheimer's disease
    Hampel, H.; Shen, Y.; Walsh, D.M.; Aisen, P.; Shaw, L.M.; Zetterberg, H.; Trojanowski, J.Q.; Blennow, K.
  • The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics
    Hardy, J.; Selkoe, D.J.
  • Alzheimer's disease: the amyloid cascade hypothesis
    Hardy, J.A.; Higgins, G.A.
  • A simple synthesis of [11C]methyl triflate
    Jewett, D.M.
  • The amyloid cascade hypothesis: are we poised for success or failure?
    Karran, E.; De Strooper, B.
  • A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
    Karran, E.; Hardy, J.
  • Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain
    Klunk, W.E.; Lopresti, B.J.; Ikonomovic, M.D.; Lefterov, I.M.; Koldamova, R.P.; Abrahamson, E.E.; Debnath, M.L.; Holt, D.P.; Huang, G.F.; Shao, L.; DeKosky, S.T.; Price, J.C.; Mathis, C.A.
  • Synthesis of 11C-iodomethane by iodination of 11C-methaneSynthesis of 11C-iodomethane by iodination of 11C-methane
    Larsen, P.; Ulin, J.; Dahlstrom, K.; Jensen, M.
  • Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography
    Maeda, J.; Ji, B.; Irie, T.; Tomiyama, T.; Maruyama, M.; Okauchi, T.; Staufenbiel, M.; Iwata, N.; Ono, M.; Saido, T.C.; Suzuki, K.; Mori, H.; Higuchi, M.; Suhara, T.
  • Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion
    Maier, F.C.; Wehrl, H.F.; Schmid, A.M.; Mannheim, J.G.; Wiehr, S.; Lerdkrai, C.; Calaminus, C.; Stahlschmidt, A.; Ye, L.; Burnet, M.; Stiller, D.; Sabri, O.; Reischl, G.; Staufenbiel, M.; Garaschuk, O.; Jucker, M.; Pichler, B.J.
  • The hunt for brain Abeta oligomers by peripherally circulating multi-functional nanoparticles: potential therapeutic approach for Alzheimer disease
    Mancini, S.; Minniti, S.; Gregori, M.; Sancini, G.; Cagnotto, A.; Couraud, P.O.; Ordonez-Gutierrez, L.; Wandosell, F.; Salmona, M.; Re, F.
  • Small-animal PET imaging of amyloid-beta plaques with [C]PiB and its multi-Modal validation in an APP/PS1 mouse model of Alzheimer's disease
    Manook, A.; Yousefi, B.H.; Willuweit, A.; Platzer, S.; Reder, S.; Voss, A.; Huisman, M.; Settles, M.; Neff, F.; Velden, J.; Schoor, M.; von der Kammer, H.; Wester, H.J.; Schwaiger, M.; Henriksen, G.; Drzezga, A.
  • Mouse MRI Brain Template. MRM NAt Mouse Brain Database
    Mouse MRI brain template
  • Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide
    Re, F.; Cambianica, I.; Sesana, S.; Salvati, E.; Cagnotto, A.; Salmona, M.; Couraud, P.O.; Moghimi, S.M.; Masserini, M.; Sancini, G.
  • Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model
    Re, F.; Cambianica, I.; Zona, C.; Sesana, S.; Gregori, M.; Rigolio, R.; La Ferla, B.; Nicotra, F.; Forloni, G.; Cagnotto, A.; Salmona, M.; Masserini, M.; Sancini, G.
  • Nanotechnology for neurodegenerative disorders
    Re, F.; Gregori, M.; Masserini, M.
  • Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET
    Rominger, A.; Brendel, M.; Burgold, S.; Keppler, K.; Baumann, K.; Xiong, G.; Mille, E.; Gildehaus, F.J.; Carlsen, J.; Schlichtiger, J.; Niedermoser, S.; Wängler, B.; Cumming, P.; Steiner, H.; Herms, J.; Haass, C.; Bartenstein, P.
  • Amyloid load and translocator protein 18 kDa in APPswePS1-dE9 mice: a longitudinal study
    Sérrière, S.; Tauber, C.; Vercouillie, J.; Mothes, C.; Pruckner, C.; Guilloteau, D.; Kassiou, M.; Doméné, A.; Garreau, L.; Page, G.; Chalon, S.
  • Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease
    Snellman, A.; López-Picón, F.R.; Rokka, J.; Salmona, M.; Forloni, G.; Scheinin, M.; Solin, O.; Rinne, J.O.; Haaparanta-Solin, M.
  • In vivo PET imaging of beta-amyloid deposition in mouse models od Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol
    Snellman, A.; Rokka, J.; López Picón, F.R.; Eskola, O.; Salmona, M.; Forloni, G.; Scheinin, M.; Solin, O.; Rinne, J.O.; Haaparanta-Solin, M.
  • Pharmacokinetics of [(18)F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease
    Snellman, A.; Rokka, J.; Lopez-Picon, F.R.; Eskola, O.; Wilson, I.; Farrar, G.; Scheinin, M.; Solin, O.; Rinne, J.O.; Haaparanta-Solin, M.
  • Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
    Sturchler-Pierrat, C.; Abramowski, D.; Duke, M.; Wiederhold, K.H.; Mistl, C.; Rothacher, S.; Ledermann, B.; Bürki, K.; Frey, P.; Paganetti, P.A.; Waridel, C.; Calhoun, M.E.; Jucker, M.; Probst, A.; Staufenbiel, M.; Sommer, B.
  • Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model
    Sturchler-Pierrat, C.; Staufenbiel, M.
  • Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria
    Wimo, A.; Ballard, C.; Brayne, C.; Gauthier, S.; Handels, R.; Jones, R.W.; Jonsson, L.; Khachaturian, A.S.; Kramberger, M.
  • MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research
    Zimmer, E.R.; Parent, M.J.; Cuello, A.C.; Gauthier, S.; Rosa-Neto, P.

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off

Sign up
for free
Start 14 day
Free Trial